Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly (LLY) is one of the stocks most watched ... as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long-term stocks. Ken Fisher is a prominent American billionaire investment analyst ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

We'll use ROE to examine Eli Lilly and Company (NYSE:LLY), by way of a worked example. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

Learn More » For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45 ...

Eli Lilly and Company has a one year low of $637.00 and a one year high of $972.53. Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Wednesday, October 30th.